Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage for Dexcom’s continuous glucose monitoring systems.* BURNABY, British ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
23h
Zacks Investment Research on MSNDXCM Inks Deal With Nanowear to Boost CGM Application Beyond DiabetesDexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...
4d
Zacks Investment Research on MSNDXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Explore more
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.
DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its glucose sensors. DexCom receives a warning letter from the FDA citing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results